Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
Biopharma revenue grew from $14.1 million to $19 million in the quarter while clinical testing revenue declined from $12 million to $9.8 million.
The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.
The results indicate that while blood-based assays can be useful, tissue biopsies should remain the gold standard when available, said one of the study authors.
FDA clearance of the first NGS companion diagnostic paves the way for other comprehensive genomic profiling tests, but Foundation will have to educate docs on the benefits of its test.
After a five-year pilot, only one company has successfully taken a test through parallel review, but there is growing industry interest.
The test is approved to identify patients who harbor BRCA mutations and are therefore more likely to respond to Clovis Oncology's ovarian cancer drug Rubraca.
A small study has found that two next-generation sequencing tests that examined the same cancers uncovered different genetic alterations.
The company reported $29.4 million in revenues for the quarter and a net loss of $31.3 million, while the number of clinical tests increased to 11,627.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.